Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 13/20 | 0.61 |
| ▸ | PTPN2 | P17706 | 2/20 | 0.57 |
| ▸ | MAOA | P21397 | 3/20 | 0.55 |
| ▸ | MAOB | P27338 | 3/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | BCHE | P06276 | 1/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11880562 | 0.88 | PTPN1 (0.58) | PTPN1PTPN2MAOAMAOBALDH1A1 | |
| SCHEMBL11878491 | 0.86 | PTPN1 (0.56) | PTPN1PTPN2MAOAMAOBALDH1A1 | |
| SCHEMBL3913372 | 0.82 | PTPN1 (0.55) | PTPN1PTPN2MAOAMAOBALDH1A1 | |
| SCHEMBL13126879 | 0.81 | TP53 (0.52) | MAOBALDH1A1CA12CA1CA2 | |
| SCHEMBL911098 | 0.80 | ALDH1A1 (0.68) | PTPN1PTPN2MAOAMAOBALDH1A1 | |
| SCHEMBL29952420 | 0.80 | ALDH1A1 (0.68) | PTPN1PTPN2MAOAMAOBALDH1A1 | |
| SCHEMBL1998830 | 0.78 | MAOB (0.62) | PTPN1PTPN2MAOAMAOBALDH1A1 | |
| SCHEMBL23707495 | 0.76 | PTPN1 (0.67) | PTPN1PTPN2MAOAMAOBALDH1A1 | |
| SCHEMBL12174817 | 0.76 | PTPN1 (0.67) | PTPN1PTPN2MAOAMAOBALDH1A1 | |
| SCHEMBL13978663 | 0.76 | PTPN1 (1.00) | PTPN1PTPN2MAOAMAOBPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117466915-A | Chromone-containing benzo [ d ] imidazo [2,1-b ] thiazole compound and preparation method and application thereof | 江西科技师范大学 | 2024-01-30 | — | — | CN | claimed |
| EP-0743574-B1 | Migration imaging members | XEROX CORP (US) | 2000-12-27 | — | — | EP | claimed |
| EP-0743573-B1 | Method for obtaining image contrast migration imaging members | XEROX CORP (US) | 2000-09-06 | — | — | EP | claimed |
| EP-0743573-A2 | Method for obtaining image contrast migration imaging members | XEROX CORPORATION (US) | 1996-11-20 | — | — | EP | claimed |
| EP-0743574-A2 | Migration imaging members | XEROX CORPORATION (US) | 1996-11-20 | — | — | EP | claimed |
| US-5563014-A | SOFTENABLE LAYER CONTAINIG PHOTOSENSITIVE MARKING MATERIAL; TRANSPARENTIZING AGENT | XEROX CORPORATION (US) | 1996-10-08 | — | — | US | claimed |
| US-5514505-A | SELECTIVE TRANSPARENTIZATION OF PHOTOSENSITIVE MIGRATION MARKING PARTICLES EMBEDDED NEAR THE SURFACE OF A SOFTENABLE LAYER SUPPORTED BY AN ELECTROCONDUCTIVE SUBSTRATE | XEROX CORPORATION (US) | 1996-05-07 | — | — | US | claimed |
| US-3984441-A | ANTIALLERGENS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JA) | 1976-10-05 | — | — | US | claimed |
| CN-117466915-A | Chromone-containing benzo [ d ] imidazo [2,1-b ] thiazole compound and preparation method and application thereof | 江西科技师范大学 | 2024-01-30 | — | — | CN | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-20110269763-A1 | CRTH2 receptor ligands for medicinal uses | 7TM PHARMA A/S (DK) | 2011-11-03 | — | — | US | disclosed |
| US-8022063-B2 | CRTH2 receptor ligands for medicinal uses | 7TM PHARMA A/S (DK) | 2011-09-20 | — | — | US | disclosed |
| EP-2336113-A1 | CRTH2 Receptor Ligands for Medical Use | 7TM Pharma A/S (DK) | 2011-06-22 | — | — | EP | disclosed |
| US-20090099189-A1 | CRTH2 Receptor Ligands For Medicinal Uses | 7TM PHARMA A/S (DK) | 2009-04-16 | — | — | US | disclosed |
| EP-0743574-B1 | Migration imaging members | XEROX CORP (US) | 2000-12-27 | — | — | EP | disclosed |
| EP-0743573-B1 | Method for obtaining image contrast migration imaging members | XEROX CORP (US) | 2000-09-06 | — | — | EP | disclosed |
| EP-0743573-A2 | Method for obtaining image contrast migration imaging members | XEROX CORPORATION (US) | 1996-11-20 | — | — | EP | disclosed |
| EP-0743574-A2 | Migration imaging members | XEROX CORPORATION (US) | 1996-11-20 | — | — | EP | disclosed |
| US-5563014-A | SOFTENABLE LAYER CONTAINIG PHOTOSENSITIVE MARKING MATERIAL; TRANSPARENTIZING AGENT | XEROX CORPORATION (US) | 1996-10-08 | — | — | US | disclosed |
| US-5514505-A | SELECTIVE TRANSPARENTIZATION OF PHOTOSENSITIVE MIGRATION MARKING PARTICLES EMBEDDED NEAR THE SURFACE OF A SOFTENABLE LAYER SUPPORTED BY AN ELECTROCONDUCTIVE SUBSTRATE | XEROX CORPORATION (US) | 1996-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099189-A1 | CRTH2 Receptor Ligands For Medicinal Uses | HRH1, HRH2, HRH3 | PTPN1 3937/4885PTPN2 3736/4885MAOA 3381/4885 |
| US-20110269763-A1 | CRTH2 receptor ligands for medicinal uses | HRH1, HRH2, HRH4 | PTPN1 3876/4885PTPN2 3983/4885MAOA 3509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.